recombinant mouse il 17ra Search Results


recombinant mouse il 17ra  (R&D Systems)
93
R&D Systems recombinant mouse il 17ra
Recombinant Mouse Il 17ra, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse il 17ra/product/R&D Systems
Average 93 stars, based on 1 article reviews
recombinant mouse il 17ra - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
recombinant mouse il 17ra il 17r fc chimera protein  (R&D Systems)
92
R&D Systems recombinant mouse il 17ra il 17r fc chimera protein
EV‐KRAS complex facilitates inflammation through the IL‐17A/FGF21 axis. (a) HE staining of lung tissue from mice (blocked with <t>IL‐17R/Fc</t> or anti‐FGF21 antibody) intratracheally administered extracellular vesicle (EV) KRAS complex (liposome‐EV‐KRAS). (b) ELISA for TNFα, IL‐17A and IL‐6 from lung tissue from mice (blocked with IL‐17R/Fc or anti‐FGF21 antibody) intratracheal administered liposome‐EV‐KRAS. (c) Adenosine triphosphate (ATP) cell proliferation assay showing proliferation of Jurkat cells in response to lung tumour lysate with and without IL‐17A depletion using IL‐17A immunoprecipitation. (d) Luciferase assay for FGF21 promotor assessment, TC1 cells treated with respective lung tumour lysate with and without IL‐17A depletion using IL‐17A immunoprecipitation. (e) Western blot for PI3K, SIRT1, NFκB‐ TC1 cells treated with respective lung tumour lysate with and without FGF21 depletion using FGF21 immunoprecipitation. (f) qRT‐PCR for genes involved in EMT pathway‐ TC1 cells treated with respective lung tumour lysate with and without FGF21 depletion using FGF21 immunoprecipitation. For in vivo treatment mice were administered with 50 μl of 10 × 1010 liposome particles/ml and for in vitro treatment 2 × 108 liposome particle/ml for respective group were used. Data are mean ± SEM from three replicates using one‐way ANOVA, ** p < 0.01.
Recombinant Mouse Il 17ra Il 17r Fc Chimera Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse il 17ra il 17r fc chimera protein/product/R&D Systems
Average 92 stars, based on 1 article reviews
recombinant mouse il 17ra il 17r fc chimera protein - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
soluble recombinant human or mouse il-17ra/fc chimeras  (Biacore)
90
Biacore soluble recombinant human or mouse il-17ra/fc chimeras
EV‐KRAS complex facilitates inflammation through the IL‐17A/FGF21 axis. (a) HE staining of lung tissue from mice (blocked with <t>IL‐17R/Fc</t> or anti‐FGF21 antibody) intratracheally administered extracellular vesicle (EV) KRAS complex (liposome‐EV‐KRAS). (b) ELISA for TNFα, IL‐17A and IL‐6 from lung tissue from mice (blocked with IL‐17R/Fc or anti‐FGF21 antibody) intratracheal administered liposome‐EV‐KRAS. (c) Adenosine triphosphate (ATP) cell proliferation assay showing proliferation of Jurkat cells in response to lung tumour lysate with and without IL‐17A depletion using IL‐17A immunoprecipitation. (d) Luciferase assay for FGF21 promotor assessment, TC1 cells treated with respective lung tumour lysate with and without IL‐17A depletion using IL‐17A immunoprecipitation. (e) Western blot for PI3K, SIRT1, NFκB‐ TC1 cells treated with respective lung tumour lysate with and without FGF21 depletion using FGF21 immunoprecipitation. (f) qRT‐PCR for genes involved in EMT pathway‐ TC1 cells treated with respective lung tumour lysate with and without FGF21 depletion using FGF21 immunoprecipitation. For in vivo treatment mice were administered with 50 μl of 10 × 1010 liposome particles/ml and for in vitro treatment 2 × 108 liposome particle/ml for respective group were used. Data are mean ± SEM from three replicates using one‐way ANOVA, ** p < 0.01.
Soluble Recombinant Human Or Mouse Il 17ra/Fc Chimeras, supplied by Biacore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/soluble recombinant human or mouse il-17ra/fc chimeras/product/Biacore
Average 90 stars, based on 1 article reviews
soluble recombinant human or mouse il-17ra/fc chimeras - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


EV‐KRAS complex facilitates inflammation through the IL‐17A/FGF21 axis. (a) HE staining of lung tissue from mice (blocked with IL‐17R/Fc or anti‐FGF21 antibody) intratracheally administered extracellular vesicle (EV) KRAS complex (liposome‐EV‐KRAS). (b) ELISA for TNFα, IL‐17A and IL‐6 from lung tissue from mice (blocked with IL‐17R/Fc or anti‐FGF21 antibody) intratracheal administered liposome‐EV‐KRAS. (c) Adenosine triphosphate (ATP) cell proliferation assay showing proliferation of Jurkat cells in response to lung tumour lysate with and without IL‐17A depletion using IL‐17A immunoprecipitation. (d) Luciferase assay for FGF21 promotor assessment, TC1 cells treated with respective lung tumour lysate with and without IL‐17A depletion using IL‐17A immunoprecipitation. (e) Western blot for PI3K, SIRT1, NFκB‐ TC1 cells treated with respective lung tumour lysate with and without FGF21 depletion using FGF21 immunoprecipitation. (f) qRT‐PCR for genes involved in EMT pathway‐ TC1 cells treated with respective lung tumour lysate with and without FGF21 depletion using FGF21 immunoprecipitation. For in vivo treatment mice were administered with 50 μl of 10 × 1010 liposome particles/ml and for in vitro treatment 2 × 108 liposome particle/ml for respective group were used. Data are mean ± SEM from three replicates using one‐way ANOVA, ** p < 0.01.

Journal: Journal of Extracellular Vesicles

Article Title: An extracellular vesicular mutant KRAS‐associated protein complex promotes lung inflammation and tumor growth

doi: 10.1002/jev2.12307

Figure Lengend Snippet: EV‐KRAS complex facilitates inflammation through the IL‐17A/FGF21 axis. (a) HE staining of lung tissue from mice (blocked with IL‐17R/Fc or anti‐FGF21 antibody) intratracheally administered extracellular vesicle (EV) KRAS complex (liposome‐EV‐KRAS). (b) ELISA for TNFα, IL‐17A and IL‐6 from lung tissue from mice (blocked with IL‐17R/Fc or anti‐FGF21 antibody) intratracheal administered liposome‐EV‐KRAS. (c) Adenosine triphosphate (ATP) cell proliferation assay showing proliferation of Jurkat cells in response to lung tumour lysate with and without IL‐17A depletion using IL‐17A immunoprecipitation. (d) Luciferase assay for FGF21 promotor assessment, TC1 cells treated with respective lung tumour lysate with and without IL‐17A depletion using IL‐17A immunoprecipitation. (e) Western blot for PI3K, SIRT1, NFκB‐ TC1 cells treated with respective lung tumour lysate with and without FGF21 depletion using FGF21 immunoprecipitation. (f) qRT‐PCR for genes involved in EMT pathway‐ TC1 cells treated with respective lung tumour lysate with and without FGF21 depletion using FGF21 immunoprecipitation. For in vivo treatment mice were administered with 50 μl of 10 × 1010 liposome particles/ml and for in vitro treatment 2 × 108 liposome particle/ml for respective group were used. Data are mean ± SEM from three replicates using one‐way ANOVA, ** p < 0.01.

Article Snippet: In vivo cytokine neutralization experiments involved administering mAbs against FGF21 (Abclonal, Woburn, MA) and recombinant Mouse IL‐17RA/IL‐17R Fc Chimera Protein (R&D System) intraperitoneally.

Techniques: Staining, Enzyme-linked Immunosorbent Assay, Proliferation Assay, Immunoprecipitation, Luciferase, Western Blot, Quantitative RT-PCR, In Vivo, In Vitro